Stocks
Funds
Screener
Sectors
Watchlists
SEER

SEER - Seer, Inc. Stock Price, Fair Value and News

$1.86-0.05 (-2.62%)
Market Closed

61/100

SEER

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

61/100

SEER

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.23

Target 3M

$1.98

Target 6M

$2.06

SEER Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SEER Price Action

Last 7 days

-1.1%

Last 30 days

2.2%

Last 90 days

-16.6%

Trailing 12 Months

-21.8%

SEER RSI Chart

SEER Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SEER Valuation

Market Cap

136.4M

Price/Earnings (Trailing)

-1.72

Price/Sales (Trailing)

8.33

EV/EBITDA

-1.25

Price/Free Cashflow

-2.96

SEER Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.23

Target 3M

$1.98

Target 6M

$2.06

SEER Fundamentals

SEER Revenue

Revenue (TTM)

16.4M

Rev. Growth (Yr)

2.21%

Rev. Growth (Qtr)

1.73%

SEER Earnings

Earnings (TTM)

-79.3M

Earnings Growth (Yr)

14.51%

Earnings Growth (Qtr)

6.13%

SEER Profitability

Operating Margin

50.72%

EBT Margin

-482.85%

Return on Equity

-29.19%

Return on Assets

-25.71%

Free Cashflow Yield

-33.77%

SEER Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202515.3M16.3M16.4M0
202415.7M14.7M14.6M14.2M
202316.2M16.6M16.8M16.7M
20229.9M12.2M14.0M15.5M
20212.1M3.6M5.1M6.6M
2020000656.0K
SEER
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Oregon Health & Science University; The Broad Institute of MIT and Harvard; Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
 CEO
 WEBSITEhttps://seer.bio
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES164

Seer, Inc. Frequently Asked Questions


SEER is the stock ticker symbol of Seer, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Seer, Inc. is 136.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SEER's fair value in chart for subscribers.

The fair value guage provides a quick view whether SEER is over valued or under valued. Whether Seer, Inc. is cheap or expensive depends on the assumptions which impact Seer, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SEER.

As of Wed Jan 28 2026, SEER's PE ratio (Price to Earnings) is -1.72 and Price to Sales (PS) ratio is 8.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SEER PE ratio will change depending on the future growth rate expectations of investors.